# Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

> **NCT01728324** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 496 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 207127-placebo: 8-week treatment
- **DRUG:** Ribavirin: 24-week treatment
- **DRUG:** BI 207127: 24-week treatment
- **DRUG:** Faldaprevir: 24-week treatment
- **DRUG:** Faldaprevir: 24-week treatment
- **DRUG:** Ribavirin-placebo: 8-week treatment
- **DRUG:** BI 207127: 24-week treatment
- **DRUG:** Faldaprevir-placebo: 8-week treatment
- **DRUG:** Faldaprevir: 16-week treatment
- **DRUG:** Ribavirin: 16-week treatment
- **DRUG:** RBV: 24-week treatment
- **DRUG:** BI 207127: 16-week treatment

## Key facts

- **NCT ID:** NCT01728324
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-02
- **Final completion:** 2015-01
- **Target enrollment:** 496 (ACTUAL)
- **Last updated:** 2016-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728324, "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01728324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*